Alnylam Sheds Legal Trouble But Picks Up Manufacturing Challenge In Tekmira Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam is paying Tekmira $65 million to resolve an RNAi trade secrets suit; the new licensing pact reduces Alnylam’s future milestone and royalty payments on three compounds and allows the firm to manufacture its own drug candidates.
You may also be interested in...
Moderna Again Faces Claims It Excluded Others’ Work In Developing COVID-19 Vaccine
Arbutus Biopharma alleges Moderna refused to license patents covering its lipid nanoparticle delivery platform in developing Spikevax. Moderna says it created its own proprietary LNP delivery technology.
Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn
Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.